




**A****Cell preparation****B****Supplementary figure 1. Dnase/Liberase treatment of spleen does not degrade IL-7Ra and DC enrichment does not affect IL-7Ra expression of ex vivo DC's.**



Supplementary figure 1. Dnase/Liberase treatment of spleens does not degrade IL-7Ra and DC enrichment does not affect IL-7Ra expression of ex vivo splenic DC's. (A) To verify that IL-7Ra is not degraded on DC's by chemical dissociation of the spleen, single cell suspensions were prepared from spleens of WT B6 mice by either mechanical disruption (left panel) or Dnase/Liberase (right panel) treatment was used. After resting the splenocytes for hour, the cells were either left un-stimulated or stimulated with IL-7 for 15 minutes. CD4 surface staining was followed by intracellular staining of pSTAT. The experiment was repeated twice (1 mouse spleen for each experiment).

(B) To verify that DC enrichment did not affect IL-7Ra expression on these cells, IL-7Ra expression of total splenocytes and enriched DC's was compared. The gating in these experiments was to CD11chi/MHCIIbright cells.





**Supplementary figure 2. IL-7Ra staining is increases during o/n culture of splenic DC's while isotype control binding to these cells remains the same.**

Supplementary figure 2. Increase of IL-7Rα antibody binding to DC's is not due to generally increased binding of antibodies to DC's. CD11cbright/MHCIIbright enriched splenic DC's were stained either with isotype control or monoclonal IL-7Rα antibody ex vivo or after overnight culture.



**Supplementary figure 3. A. Gating strategy for lymph nodes DC's. B IL-7Ra and CD80 in lymph node DC's cultured under different stimulations.**

Supplementary figure 3. Gating strategy and CD80 and IL-7Ra expression in lymph node DC's cultured in IL-7 and IL-4. A. Gating strategy to identify DC's in murine lymph nodes. Lymph nodes from three mice were collected and pooled. Single cell suspensions and DC enrichment were performed similarly to splenocytes. Cells were then stained for DC markers. B. IL-7Ra and CD80 surface markers from lymph node DC's were measured either *ex vivo* or after overnight culture with indicated stimulations. The analysis of three independent experiments (9 mice overall) are indicated.

**A****B**

**Supplementary figure 4. Gating strategy for splenic T-cells in mice undergoing anti-IL-4 (A) or anti-IL-4 - IL-4 complex (B) administration.**

Supplementary figure 4. Gating strategy for splenic T cells from IL-4 treated mice. Spleens were harvested either from control mice (anti-IL-4-treated mice, A) or mice receiving IL-4 (IL-4 complexed to anti-IL-4, B). CD3 positive cells were further divided to CD4 or CD8 positive cells as indicated. Similar analysis was performed for all treated mice (5 controls and 5 IL-4 treated mice).